中华预防医学杂志
中華預防醫學雜誌
중화예방의학잡지
CHINESE JOURNAL OF
2012年
6期
510-513
,共4页
卢莉%李晓梅%刘东磊%张合润%张朱佳子%王海红%刘芳%宁召起%张丽文%褚平%解艳涛%许颖%李娟%庞星火%邓瑛
盧莉%李曉梅%劉東磊%張閤潤%張硃佳子%王海紅%劉芳%寧召起%張麗文%褚平%解豔濤%許穎%李娟%龐星火%鄧瑛
로리%리효매%류동뢰%장합윤%장주가자%왕해홍%류방%저소기%장려문%저평%해염도%허영%리연%방성화%산영
脊髓灰质炎%疫苗,灭活%疫苗,减毒%免疫活性%序贯程序
脊髓灰質炎%疫苗,滅活%疫苗,減毒%免疫活性%序貫程序
척수회질염%역묘,멸활%역묘,감독%면역활성%서관정서
Poliomyelitis%Vaccines,inactivated%Vaccines,attenuated%Immunocompetence%Sequential program
目的 评价脊髓灰质炎灭活疫苗( inactivated polio vaccine,IPV)与脊髓灰质炎减毒活疫苗(oral polio vaccine,OPV)不同序贯免疫程序的基础免疫效果.方法 选择在北京居住的≥2月龄(60 ～89 d)婴儿,分为1剂IPV和2剂OPV序贯(I-O-O,122名)、2剂IPV和1剂OPV序贯(I-I-O,103名)、IPV全程(I-I-I,114名)、OPV全程(O-O-O,106名)共4组,分别在2、3、4月龄时接种.检测其血清中脊髓灰质炎中和抗体,以及接种1剂和2剂IPV后的抗体滴度,计算各组保护率.结果 完成基础免疫后,O-O-O组Ⅰ、Ⅱ、Ⅲ型抗体几何平均滴度(GMT)分别为788.32、738.42、631.17,I-I-I组分别为212.02、262.30、537.52,I-O-O组分别为940.35、929.72、940.35,I-I-O组分别为901.09、1102.68、1110.12,差异均有统计学意义(F值分别为47.71、53.84、9.81,P值均＜0.01)；各组3个型别的抗体保护率为98.1％ (104/106)～100.0％,差异无统计学意义(P＞0.05).接种第1剂IPV后,I-O-O组Ⅰ、Ⅱ、Ⅲ型抗体GMT分别为18.88、37.77、24.64,保护率为82.6％( 122/138) ～ 96.4％(133/138)；接种第2剂IPV后,I-I-O组Ⅰ、Ⅱ、Ⅲ型抗体GMT分别为177.03、168.25、321.86,保护率为99.1％ (108/109)～100.0％(109/109).结论 IPV与OPV序贯接种后,脊髓灰质炎中和抗体GMT比单独接种3剂IPV或3剂OPV高；序贯程序中,接种2剂IPV后抗体保护率达到较高水平,有利于减少疫苗相关麻痹病例(VAPP).为维持高水平免疫屏障并避免VAPP发生,可采用IPV与OPV序贯程序,并以2剂IPV的序贯程序为首选.
目的 評價脊髓灰質炎滅活疫苗( inactivated polio vaccine,IPV)與脊髓灰質炎減毒活疫苗(oral polio vaccine,OPV)不同序貫免疫程序的基礎免疫效果.方法 選擇在北京居住的≥2月齡(60 ～89 d)嬰兒,分為1劑IPV和2劑OPV序貫(I-O-O,122名)、2劑IPV和1劑OPV序貫(I-I-O,103名)、IPV全程(I-I-I,114名)、OPV全程(O-O-O,106名)共4組,分彆在2、3、4月齡時接種.檢測其血清中脊髓灰質炎中和抗體,以及接種1劑和2劑IPV後的抗體滴度,計算各組保護率.結果 完成基礎免疫後,O-O-O組Ⅰ、Ⅱ、Ⅲ型抗體幾何平均滴度(GMT)分彆為788.32、738.42、631.17,I-I-I組分彆為212.02、262.30、537.52,I-O-O組分彆為940.35、929.72、940.35,I-I-O組分彆為901.09、1102.68、1110.12,差異均有統計學意義(F值分彆為47.71、53.84、9.81,P值均＜0.01)；各組3箇型彆的抗體保護率為98.1％ (104/106)～100.0％,差異無統計學意義(P＞0.05).接種第1劑IPV後,I-O-O組Ⅰ、Ⅱ、Ⅲ型抗體GMT分彆為18.88、37.77、24.64,保護率為82.6％( 122/138) ～ 96.4％(133/138)；接種第2劑IPV後,I-I-O組Ⅰ、Ⅱ、Ⅲ型抗體GMT分彆為177.03、168.25、321.86,保護率為99.1％ (108/109)～100.0％(109/109).結論 IPV與OPV序貫接種後,脊髓灰質炎中和抗體GMT比單獨接種3劑IPV或3劑OPV高；序貫程序中,接種2劑IPV後抗體保護率達到較高水平,有利于減少疫苗相關痳痺病例(VAPP).為維持高水平免疫屏障併避免VAPP髮生,可採用IPV與OPV序貫程序,併以2劑IPV的序貫程序為首選.
목적 평개척수회질염멸활역묘( inactivated polio vaccine,IPV)여척수회질염감독활역묘(oral polio vaccine,OPV)불동서관면역정서적기출면역효과.방법 선택재북경거주적≥2월령(60 ～89 d)영인,분위1제IPV화2제OPV서관(I-O-O,122명)、2제IPV화1제OPV서관(I-I-O,103명)、IPV전정(I-I-I,114명)、OPV전정(O-O-O,106명)공4조,분별재2、3、4월령시접충.검측기혈청중척수회질염중화항체,이급접충1제화2제IPV후적항체적도,계산각조보호솔.결과 완성기출면역후,O-O-O조Ⅰ、Ⅱ、Ⅲ형항체궤하평균적도(GMT)분별위788.32、738.42、631.17,I-I-I조분별위212.02、262.30、537.52,I-O-O조분별위940.35、929.72、940.35,I-I-O조분별위901.09、1102.68、1110.12,차이균유통계학의의(F치분별위47.71、53.84、9.81,P치균＜0.01)；각조3개형별적항체보호솔위98.1％ (104/106)～100.0％,차이무통계학의의(P＞0.05).접충제1제IPV후,I-O-O조Ⅰ、Ⅱ、Ⅲ형항체GMT분별위18.88、37.77、24.64,보호솔위82.6％( 122/138) ～ 96.4％(133/138)；접충제2제IPV후,I-I-O조Ⅰ、Ⅱ、Ⅲ형항체GMT분별위177.03、168.25、321.86,보호솔위99.1％ (108/109)～100.0％(109/109).결론 IPV여OPV서관접충후,척수회질염중화항체GMT비단독접충3제IPV혹3제OPV고；서관정서중,접충2제IPV후항체보호솔체도교고수평,유리우감소역묘상관마비병례(VAPP).위유지고수평면역병장병피면VAPP발생,가채용IPV여OPV서관정서,병이2제IPV적서관정서위수선.
Objective To evaluate immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV).Methods Children of 2 months old(60 -89 days) selected in Beijing were assigned to 4 groups,1 dose IPV plus 2 doses OPV (I-O-O,122 children ),2 doses IPV plus 1 dose OPV (I-I-O,103 children),3 doses IPV (I-I-I,114 children),and 3 doses OPV(O-O-O,106 children),and were vaccinated at the age of 2,3,4months.Polio neutralizing antibody titers against poliovirus types 1,2,and 3 were tested and protective rates were calculated before the 1st dose,after the last dose,and after the 1st and 2nd dose of IPV.Results After the primary immunization,geometric mean titers ( GMT ) of polio neutralizing antibody titers against poliovirus types 1,2,and 3 were 788.32,738.42 and 631.17 in O-O-O group,212.02,262.30 and 537.52 in I-I-I group,940.35,929.72 and 940.35 in I-O-O group and 901.09,1102.68 and 1110.12 in I-I-O group ( F values were 47.71,53.84,and 9.81 respectively,all P values ＜0.01 ).The protective rate of three types among each group was 98.1％ (104/106) - 100.0％ and the difference was not statistically significant (P＞0.05).After the 1st dose of IPV,the GMT were 18.88,37.77,24.64 and the protective rate was 82.6％ (122/138) -96.4％ (133/138) ; after the 2nd dose of IPV,GMT were 177.03,168.25,321.86 and the protective rate was 99.1％ (108/109) - 100.0％ ( 109/109 ) in antibody types 1,2 and 3,respectively.Conclusion GMT of polio neutralizing antibody titers against poliovirus is higher after vaccination by sequential program of IPV and OPV than that by IPV or OPV 3-doses program.High level of protective rate after 2 doses of IPV in I-I-O group may lead to better protection from vaccine associated paralytic poliomyelitis(VAPP).Sequential program of IPV and OPV can be used to maintain high level of herd immunity and to prevent VAPP,and the I-I-O sequential program should be the first choice.
